Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cerebral thrombosis associated with Amicar therapy.

E P Hoffman, A H Koo

    Radiology
    |June 1, 1979
    PubMed
    Summary
    This summary is machine-generated.

    Amicar (epsilon-aminocaproic acid) may increase cerebral thrombosis risk in subarachnoid hemorrhage patients. Further screening is crucial to identify individuals at higher risk during Amicar treatment.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Facilitating orphan drug development: Proceedings of the TREAT-NMD International Conference, December 2015, Washington, DC, USA.

    Neuromuscular disorders : NMD·2017
    Same author

    Mosaic focal dermal hypoplasia caused by a novel somatic mutation in PORCN detected in affected skin.

    The British journal of dermatology·2015
    Same author

    Leptin and leptin receptor genetic variants associate with habitual physical activity and the arm body composition response to resistance training.

    Gene·2012
    Same author

    SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy: predicting the severity of Duchenne muscular dystrophy: implications for treatment.

    Neurology·2011
    Same author

    SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy.

    Neurology·2010
    Same author

    Adiposity attenuates muscle quality and the adaptive response to resistance exercise in non-obese, healthy adults.

    International journal of obesity (2005)·2010

    Area of Science:

    • Neurology
    • Vascular Medicine
    • Pharmacology

    Background:

    • Amicar (epsilon-aminocaproic acid) is utilized to enhance clot formation in patients experiencing subarachnoid hemorrhage.
    • Previous reports indicate a potential association between Amicar use and the occurrence of cerebral thrombosis in diverse vascular areas.

    Observation:

    • The study details two patients who underwent cerebral angiography following Amicar therapy.
    • Angiography revealed cerebral thrombosis that was independent of vasospasm or procedural complications.

    Findings:

    • Cerebral thrombosis was observed in patients treated with Amicar for subarachnoid hemorrhage.
    • The identified thrombosis was not attributable to vascular spasm or technical issues during angiography.

    Related Experiment Videos

    Implications:

    • These findings suggest a potential thrombotic risk associated with Amicar therapy.
    • Implementing careful patient screening is recommended to assess the risk of thrombosis in individuals receiving Amicar.